Sagimet Biosciences Inc. (NASDAQ:SGMT) Cantor Global Healthcare Conference 2025 September 3, 2025 1:35 PM EDT
Company Participants
David Happel – CEO, President & Director
Eduardo Martins – Chief Medical Officer
Robert D’Urso – Senior Vice President of New Products
Conference Call Participants
Prakhar Agrawal – Cantor Fitzgerald & Co., Research Division
Presentation
Prakhar Agrawal
Senior Biotech Analyst
All right. Hello, everyone. My name is Prakhar Agrawal. I’m a biotech analyst at Cantor. Welcome to day 1 of Cantor’s Global Healthcare Conference. And for the next session, we are very excited to host the team of Sagimet Bio. Representing Sagimet today, we have Dave Happel, CEO; Dr. Eduardo Martins, CMO; and Rob D’Urso, SVP, New Products. Gentlemen, thank you for making time.
David Happel
CEO, President & Director
Thanks, Prakhar.
Eduardo Martins
Chief Medical Officer
Thank you.
Question-and-Answer Session
Prakhar Agrawal
Cantor Fitzgerald & Co., Research Division
Maybe for folks who are not familiar with the company, just maybe start off with an overview of the company and the key priorities right now.
David Happel
CEO, President & Director
Sure. So Sagimet is a clinical stage biopharmaceutical company that is targeting and focused on developing programs that blunt or inhibit fatty acid synthase or FASN. FASN is a rather ubiquitous enzyme within the body that functions as a regulator in particular organs and pathways. But when it becomes over-expressed or overactive, then bad things happen as it does in the indications that we’re pursuing primary development right now, which is in MASH, acne and certain solid tumors in oncology that require fasten for progression of disease.
The bulk of our work has been done in MASH and acne. In MASH, we’ve conducted preclinical and clinical studies that show much the same thing. That is that our lead program, our lead molecule, denifanstat actually does a very effective job of
